# Official Journal C 343/2013

| | ISSN 1977-091X
  doi:10.3000/1977091X.C_2013.343.eng |
| --- | --- |
| Official Journal
  of the European Union | C 343 |
| | |
| English edition | Information and Notices | Volume 5623 November 2013 |

ISSN 1977-091X

doi:10.3000/1977091X.C_2013.343.eng

Official Journal

of the European Union

C 343

English edition

Information and Notices

Volume 5623 November 2013

---

| Notice No | Contents | page |
| --- | --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2013/C 343/01 | Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (
  1
  ) | 1 |
| 2013/C 343/02 | Non-opposition to a notified concentration (Case COMP/M.6922 — Triton/Logstor) (
  1
  ) | 15 |
| 2013/C 343/03 | Non-opposition to a notified concentration (Case COMP/M.6995 — Reggeborgh/Boskalis/VSMC) (
  1
  ) | 15 |
| 2013/C 343/04 | Non-opposition to a notified concentration (Case COMP/M.7069 — Ares/OTPP/CPG) (
  1
  ) | 16 |
| 2013/C 343/05 | Non-opposition to a notified concentration (Case COMP/M.7031 — Eurenco/Maxamchem/Manuco) (
  1
  ) | 16 |

Notice No

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2013/C 343/01

Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (
  1
  )

1

1

2013/C 343/02

Non-opposition to a notified concentration (Case COMP/M.6922 — Triton/Logstor) (
  1
  )

1

15

2013/C 343/03

Non-opposition to a notified concentration (Case COMP/M.6995 — Reggeborgh/Boskalis/VSMC) (
  1
  )

1

15

2013/C 343/04

Non-opposition to a notified concentration (Case COMP/M.7069 — Ares/OTPP/CPG) (
  1
  )

1

16

2013/C 343/05

Non-opposition to a notified concentration (Case COMP/M.7031 — Eurenco/Maxamchem/Manuco) (
  1
  )

1

16

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2013/C 343/06 | Euro exchange rates | 17 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2013/C 343/06

Euro exchange rates

17

| | V   Announcements |
| --- | --- |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY |
| | European Commission |
| 2013/C 343/07 | Prior notification of a concentration (Case COMP/M.7107 — Cordes & Graefe/Pompac/Comafranc) (
  1
  ) | 18 |
| 2013/C 343/08 | Prior notification of a concentration (Case COMP/M.6981 — TPG/Servco/Fender) — Candidate case for simplified procedure (
  1
  ) | 19 |
| 2013/C 343/09 | Prior notification of a concentration (Case COMP/M.7079 — Bulgaria Airways Group/Swissport International/Swissport Bulgaria) — Candidate case for simplified procedure (
  1
  ) | 20 |
| | OTHER ACTS |
| | European Commission |
| 2013/C 343/10 | Reply to complaint CHAP(2013) 3076 | 21 |

V   Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

2013/C 343/07

Prior notification of a concentration (Case COMP/M.7107 — Cordes & Graefe/Pompac/Comafranc) (
  1
  )

1

18

2013/C 343/08

Prior notification of a concentration (Case COMP/M.6981 — TPG/Servco/Fender) — Candidate case for simplified procedure (
  1
  )

1

19

2013/C 343/09

Prior notification of a concentration (Case COMP/M.7079 — Bulgaria Airways Group/Swissport International/Swissport Bulgaria) — Candidate case for simplified procedure (
  1
  )

1

20

OTHER ACTS

European Commission

2013/C 343/10

Reply to complaint CHAP(2013) 3076

21

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

II Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 23.11.2013 | EN | Official Journal of the European Union | C 343/1 |
| --- | --- | --- | --- |

23.11.2013

EN

Official Journal of the European Union

C 343/1

---

Guidelines

of 5 November 2013

on Good Distribution Practice of medicinal products for human use

(Text with EEA relevance)

2013/C 343/01

INTRODUCTION

These Guidelines are based on Article 84 and Article 85b(3) of Directive 2001/83/EC (1).

The Commission has published EU Guidelines on Good Distribution Practice (GDP) in 1994 (2). Revised guidelines were published in March 2013 (3) in order to take into account recent advances in practices for appropriate storage and distribution of medicinal products in the European Union, as well as new requirements introduced by Directive 2011/62/EU (4).

This version corrects factual mistakes identified in subchapters 5.5 and 6.3 of the revised guidelines. It also gives more explanations on the rationale for the revision as well as a date of coming into operation.

It replaces the guidelines on GDP published in March 2013.

The wholesale distribution of medicinal products is an important activity in integrated supply chain management. Today’s distribution network for medicinal products is increasingly complex and involves many players. These Guidelines lay down appropriate tools to assist wholesale distributors in conducting their activities and to prevent falsified medicines from entering the legal supply chain. Compliance with these Guidelines will ensure control of the distribution chain and consequently maintain the quality and the integrity of medicinal products.

According to Article 1(17) of Directive 2001/83/EC, wholesale distribution of medicinal products is ‘all activities consisting of procuring, holding, supplying or exporting medicinal products, apart from supplying medicinal products to the public. Such activities are carried out with manufacturers or their depositories, importers, other wholesale distributors or with pharmacists and persons authorized or entitled to supply medicinal products to the public in the Member State concerned’.

Any person acting as a wholesale distributor has to hold a wholesale distribution authorisation. Article 80(g) of Directive 2001/83/EC provides that distributors must comply with the principles of and guidelines for GDP.

Possession of a manufacturing authorisation includes authorisation to distribute the medicinal products covered by the authorisation. Manufacturers performing any distribution activities with their own products must therefore comply with GDP.

The definition of wholesale distribution does not depend on whether that distributor is established or operating in specific customs areas, such as in free zones or in free warehouses. All obligations related to wholesale distribution activities (such as exporting, holding or supplying) also apply to these distributors. Relevant sections of these Guidelines should also be adhered to by other actors involved in the distribution of medicinal products.

Other actors such as brokers may also play a role in the distribution channel for medicinal products. According to Article 85b of Directive 2001/83/EC, persons brokering medicinal products must be subject to certain provisions applicable to wholesale distributors, as well as specific provisions on brokering.

CHAPTER 1 —   QUALITY MANAGEMENT

1.1.   Principle

Wholesale distributors must maintain a quality system setting out responsibilities, processes and risk management principles in relation to their activities (5). All distribution activities should be clearly defined and systematically reviewed. All critical steps of distribution processes and significant changes should be justified and where relevant validated. The quality system is the responsibility of the organisation’s management and requires their leadership and active participation and should be supported by staff commitment.

1.2.   Quality system

The system for managing quality should encompass the organisational structure, procedures, processes and resources, as well as activities necessary to ensure confidence that the product delivered maintains its quality and integrity and remains within the legal supply chain during storage and/or transportation.

The quality system should be fully documented and its effectiveness monitored. All quality-system-related activities should be defined and documented. A quality manual or equivalent documentation approach should be established.

A responsible person should be appointed by the management, who should have clearly specified authority and responsibility for ensuring that a quality system is implemented and maintained.

The management of the distributor should ensure that all parts of the quality system are adequately resourced with competent personnel, and suitable and sufficient premises, equipment and facilities.

The size, structure and complexity of distributor’s activities should be taken into consideration when developing or modifying the quality system.

A change control system should be in place. This system should incorporate quality risk management principles, and be proportionate and effective.

The quality system should ensure that:

| (i) | medicinal products are procured, held, supplied or exported in a way that is compliant with the requirements of GDP; |
| --- | --- |

(i)

medicinal products are procured, held, supplied or exported in a way that is compliant with the requirements of GDP;

| (ii) | management responsibilities are clearly specified; |
| --- | --- |

(ii)

management responsibilities are clearly specified;

| (iii) | products are delivered to the right recipients within a satisfactory time period; |
| --- | --- |

(iii)

products are delivered to the right recipients within a satisfactory time period;

| (iv) | records are made contemporaneously; |
| --- | --- |

(iv)

records are made contemporaneously;

| (v) | deviations from established procedures are documented and investigated; |
| --- | --- |

(v)

deviations from established procedures are documented and investigated;

| (vi) | appropriate corrective and preventive actions (commonly known as ‘CAPA’) are taken to correct deviations and prevent them in line with the principles of quality risk management. |
| --- | --- |

(vi)

appropriate corrective and preventive actions (commonly known as ‘CAPA’) are taken to correct deviations and prevent them in line with the principles of quality risk management.

1.3.   Management of outsourced activities

The quality system should extend to the control and review of any outsourced activities related to the procurement, holding, supply or export of medicinal products. These processes should incorporate quality risk management and include:

| (i) | assessing the suitability and competence of the contract acceptor to carry out the activity and checking authorisation status, if required; |
| --- | --- |

(i)

assessing the suitability and competence of the contract acceptor to carry out the activity and checking authorisation status, if required;

| (ii) | defining the responsibilities and communication processes for the quality-related activities of the parties involved; |
| --- | --- |

(ii)

defining the responsibilities and communication processes for the quality-related activities of the parties involved;

| (iii) | monitoring and review of the performance of the contract acceptor, and the identification and implementation of any required improvements on a regular basis. |
| --- | --- |

(iii)

monitoring and review of the performance of the contract acceptor, and the identification and implementation of any required improvements on a regular basis.

1.4.   Management review and monitoring

The management should have a formal process for reviewing the quality system on a periodic basis. The review should include:

| (i) | measurement of the achievement of quality system objectives; |
| --- | --- |

(i)

measurement of the achievement of quality system objectives;

| (ii) | assessment of performance indicators that can be used to monitor the effectiveness of processes within the quality system, such as complaints, deviations, CAPA, changes to processes; feedback on outsourced activities; self-assessment processes including risk assessments and audits; and external assessments such as inspections, findings and customer audits; |
| --- | --- |

(ii)

assessment of performance indicators that can be used to monitor the effectiveness of processes within the quality system, such as complaints, deviations, CAPA, changes to processes; feedback on outsourced activities; self-assessment processes including risk assessments and audits; and external assessments such as inspections, findings and customer audits;

| (iii) | emerging regulations, guidance and quality issues that can impact the quality management system; |
| --- | --- |

(iii)

emerging regulations, guidance and quality issues that can impact the quality management system;

| (iv) | innovations that might enhance the quality system; |
| --- | --- |

(iv)

innovations that might enhance the quality system;

| (v) | changes in business environment and objectives. |
| --- | --- |

(v)

changes in business environment and objectives.

The outcome of each management review of the quality system should be documented in a timely manner and effectively communicated internally.

1.5.   Quality risk management

Quality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of medicinal products. It can be applied both proactively and retrospectively.

Quality risk management should ensure that the evaluation of the risk to quality is based on scientific knowledge, experience with the process and ultimately links to the protection of the patient. The level of effort, formality and documentation of the process should be commensurate with the level of risk. Examples of the processes and applications of quality risk management can be found in guideline Q9 of the International Conference on Harmonisation (‘ICH’).

CHAPTER 2 —   PERSONNEL

2.1.   Principle

The correct distribution of medicinal products relies upon people. For this reason, there must be sufficient competent personnel to carry out all the tasks for which the wholesale distributor is responsible. Individual responsibilities should be clearly understood by the staff and be recorded.

2.2.   Responsible person

The wholesale distributor must designate a person as responsible person. The responsible person should meet the qualifications and all conditions provided for by the legislation of the Member State concerned (6). A degree in pharmacy is desirable. The responsible person should have appropriate competence and experience as well as knowledge of and training in GDP.

The responsible person should fulfil their responsibilities personally and should be continuously contactable. The responsible person may delegate duties but not responsibilities.

The written job description of the responsible person should define their authority to take decisions with regard to their responsibilities. The wholesale distributor should give the responsible person the defined authority, resources and responsibility needed to fulfil their duties.

The responsible person should carry out their duties in such a way as to ensure that the wholesale distributor can demonstrate GDP compliance and that public service obligations are met.

The responsibilities of the responsible person include:

| (i) | ensuring that a quality management system is implemented and maintained; |
| --- | --- |

(i)

ensuring that a quality management system is implemented and maintained;

| (ii) | focusing on the management of authorised activities and the accuracy and quality of records; |
| --- | --- |

(ii)

focusing on the management of authorised activities and the accuracy and quality of records;

| (iii) | ensuring that initial and continuous training programmes are implemented and maintained; |
| --- | --- |

(iii)

ensuring that initial and continuous training programmes are implemented and maintained;

| (iv) | coordinating and promptly performing any recall operations for medicinal products; |
| --- | --- |

(iv)

coordinating and promptly performing any recall operations for medicinal products;

| (v) | ensuring that relevant customer complaints are dealt with effectively; |
| --- | --- |

(v)

ensuring that relevant customer complaints are dealt with effectively;

| (vi) | ensuring that suppliers and customers are approved; |
| --- | --- |

(vi)

ensuring that suppliers and customers are approved;

| (vii) | approving any subcontracted activities which may impact on GDP; |
| --- | --- |

(vii)

approving any subcontracted activities which may impact on GDP;

| (viii) | ensuring that self-inspections are performed at appropriate regular intervals following a prearranged programme and necessary corrective measures are put in place; |
| --- | --- |

(viii)

ensuring that self-inspections are performed at appropriate regular intervals following a prearranged programme and necessary corrective measures are put in place;

| (ix) | keeping appropriate records of any delegated duties; |
| --- | --- |

(ix)

keeping appropriate records of any delegated duties;

| (x) | deciding on the final disposition of returned, rejected, recalled or falsified products; |
| --- | --- |

(x)

deciding on the final disposition of returned, rejected, recalled or falsified products;

| (xi) | approving any returns to saleable stock; |
| --- | --- |

(xi)

approving any returns to saleable stock;

| (xii) | ensuring that any additional requirements imposed on certain products by national law are adhered to (7). |
| --- | --- |

(xii)

ensuring that any additional requirements imposed on certain products by national law are adhered to (7).

2.3.   Other personnel

There should be an adequate number of competent personnel involved in all stages of the wholesale distribution activities of medicinal products. The number of personnel required will depend on the volume and scope of activities.

The organisational structure of the wholesale distributor should be set out in an organisation chart. The role, responsibilities, and interrelationships of all personnel should be clearly indicated.

The role and responsibilities of employees working in key positions should be set out in written job descriptions, along with any arrangements for deputising.

2.4.   Training

All personnel involved in wholesale distribution activities should be trained on the requirements of GDP. They should have the appropriate competence and experience prior to commencing their tasks.

Personnel should receive initial and continuing training relevant to their role, based on written procedures and in accordance with a written training programme. The responsible person should also maintain their competence in GDP through regular training.

In addition, training should include aspects of product identification and avoidance of falsified medicines entering the supply chain.

Personnel dealing with any products which require more stringent handling conditions should receive specific training. Examples of such products include hazardous products, radioactive materials, products presenting special risks of abuse (including narcotic and psychotropic substances), and temperature-sensitive products.

A record of all training should be kept, and the effectiveness of training should be periodically assessed and documented.

2.5.   Hygiene

Appropriate procedures relating to personnel hygiene, relevant to the activities being carried out, should be established and observed. Such procedures should cover health, hygiene and clothing.

CHAPTER 3 —   PREMISES AND EQUIPMENT

3.1.   Principle

Wholesale distributors must have suitable and adequate premises, installations and equipment (8), so as to ensure proper storage and distribution of medicinal products. In particular, the premises should be clean, dry and maintained within acceptable temperature limits.

3.2.   Premises

The premises should be designed or adapted to ensure that the required storage conditions are maintained. They should be suitably secure, structurally sound and of sufficient capacity to allow safe storage and handling of the medicinal products. Storage areas should be provided with adequate lighting to enable all operations to be carried out accurately and safely.

Where premises are not directly operated by the wholesale distributor, a contract should be in place. The contracted premises should be covered by a separate wholesale distribution authorisation.

Medicinal products should be stored in segregated areas which are clearly marked and have access restricted to authorised personnel. Any system replacing physical segregation, such as electronic segregation based on a computerised system, should provide equivalent security and should be validated.

Products pending a decision as to their disposition or products that have been removed from saleable stock should be segregated either physically or through an equivalent electronic system. This includes, for example, any product suspected of falsification and returned products. Medicinal products received from a third country but not intended for the Union market should also be physically segregated. Any falsified medicinal products, expired products, recalled products and rejected products found in the supply chain should be immediately physically segregated and stored in a dedicated area away from all other medicinal products. The appropriate degree of security should be applied in these areas to ensure that such items remain separate from saleable stock. These areas should be clearly identified.

Special attention should be paid to the storage of products with specific handling instructions as specified in national law. Special storage conditions (and special authorisations) may be required for such products (e.g. narcotics and psychotropic substances).

Radioactive materials and other hazardous products, as well as products presenting special safety risks of fire or explosion (e.g. medicinal gases, combustibles, flammable liquids and solids), should be stored in one or more dedicated areas subject to local legislation and appropriate safety and security measures.

Receiving and dispatch bays should protect products from prevailing weather conditions. There should be adequate separation between the receipt and dispatch and storage areas. Procedures should be in place to maintain control of inbound/outbound goods. Reception areas where deliveries are examined following receipt should be designated and suitably equipped.

Unauthorised access to all areas of the authorised premises should be prevented. Prevention measures would usually include a monitored intruder alarm system and appropriate access control. Visitors should be accompanied.

Premises and storage facilities should be clean and free from litter and dust. Cleaning programmes, instructions and records should be in place. Appropriate cleaning equipment and cleaning agents should be chosen and used so as not to present a source of contamination.

Premises should be designed and equipped so as to afford protection against the entry of insects, rodents or other animals. A preventive pest control programme should be in place.

Rest, wash and refreshment rooms for employees should be adequately separated from the storage areas. The presence of food, drink, smoking material or medicinal products for personal use should be prohibited in the storage areas.

3.2.1.   Temperature and environment control

Suitable equipment and procedures should be in place to check the environment where medicinal products are stored. Environmental factors to be considered include temperature, light, humidity and cleanliness of the premises.

An initial temperature mapping exercise should be carried out on the storage area before use, under representative conditions. Temperature monitoring equipment should be located according to the results of the mapping exercise, ensuring that monitoring devices are positioned in the areas that experience the extremes of fluctuations. The mapping exercise should be repeated according to the results of a risk assessment exercise or whenever significant modifications are made to the facility or the temperature controlling equipment. For small premises of a few square meters which are at room temperature, an assessment of potential risks (e.g. heaters) should be conducted and temperature monitors placed accordingly.

3.3.   Equipment

All equipment impacting on storage and distribution of medicinal products should be designed, located and maintained to a standard which suits its intended purpose. Planned maintenance should be in place for key equipment vital to the functionality of the operation.

Equipment used to control or to monitor the environment where the medicinal products are stored should be calibrated at defined intervals based on a risk and reliability assessment.

Calibration of equipment should be traceable to a national or international measurement standard. Appropriate alarm systems should be in place to provide alerts when there are excursions from pre-defined storage conditions. Alarm levels should be appropriately set and alarms should be regularly tested to ensure adequate functionality.

Equipment repair, maintenance and calibration operations should be carried out in such a way that the integrity of the medicinal products is not compromised.

Adequate records of repair, maintenance and calibration activities for key equipment should be made and the results should be retained. Key equipment would include for example cold stores, monitored intruder alarm and access control systems, refrigerators, thermo hygrometers, or other temperature and humidity recording devices, air handling units and any equipment used in conjunction with the onward supply chain.

3.3.1.   Computerised systems

Before a computerised system is brought into use, it should be demonstrated, through appropriate validation or verification studies, that the system is capable of achieving the desired results accurately, consistently and reproducibly.

A written, detailed description of the system should be available (including diagrams where appropriate). This should be kept up-to-date. The document should describe principles, objectives, security measures, system scope and main features, how the computerised system is used and the way it interacts with other systems.

Data should only be entered into the computerised system or amended by persons authorised to do so.

Data should be secured by physical or electronic means and protected against accidental or unauthorised modifications. Stored data should be checked periodically for accessibility. Data should be protected by backing up at regular intervals. Back up data should be retained for the period stated in national legislation but at least five years at a separate and secure location.

Procedures to be followed if the system fails or breaks down should be defined. This should include systems for the restoration of data.

3.3.2.   Qualification and validation

Wholesale distributors should identify what key equipment qualification and/or key process validation is necessary to ensure correct installation and operation. The scope and extent of such qualification and/or validation activities (such as storage, pick and pack processes) should be determined using a documented risk assessment approach.

Equipment and processes should be respectively qualified and/or validated before commencing use and after any significant changes, e.g. repair or maintenance.

Validation and qualification reports should be prepared summarising the results obtained and commenting on any observed deviations. Deviations from established procedures should be documented and further actions decided to correct deviations and avoid their reoccurrence (corrective and preventive actions). The principles of CAPA should be applied where necessary. Evidence of satisfactory validation and acceptance of a process or piece of equipment should be produced and approved by appropriate personnel.

CHAPTER 4 —   DOCUMENTATION

4.1.   Principle

Good documentation constitutes an essential part of the quality system. Written documentation should prevent errors from spoken communication and permits the tracking of relevant operations during the distribution of medicinal products.

4.2.   General

Documentation comprises all written procedures, instructions, contracts, records and data, in paper or in electronic form. Documentation should be readily available/retrievable.

With regard to the processing of personal data of employees, complainants or any other natural person, Directive 95/46/EC (9) on the protection of individuals applies to the processing of personal data and to the free movement of such data.

Documentation should be sufficiently comprehensive with respect to the scope of the wholesale distributor’s activities and in a language understood by personnel. It should be written in clear, unambiguous language and be free from errors.

Procedure should be approved signed and dated by the responsible person. Documentation should be approved, signed and dated by appropriate authorised persons, as required. It should not be hand-written; although, where it is necessary, sufficient space should be provided for such entries.

Any alteration made in the documentation should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded.

Documents should be retained for the period stated in national legislation but at least five years. Personal data should be deleted or anonymised as soon as their storage is no longer than necessary for the purpose of distribution activities.

Each employee should have ready access to all necessary documentation for the tasks executed.

Attention should be paid to using valid and approved procedures. Documents should have unambiguous content; title, nature and purpose should be clearly stated. Documents should be reviewed regularly and kept up-to-date. Version control should be applied to procedures. After revision of a document, a system should exist to prevent inadvertent use of the superseded version. Superseded or obsolete procedures should be removed from workstations and archived.

Records must be kept either in the form of purchase/sales invoices, delivery slips, or on computer or any other form, for any transaction in medicinal products received, supplied or brokered.

Records must include at least the following information: date; name of the medicinal product; quantity received, supplied or brokered; name and address of the supplier, customer, broker or consignee, as appropriate; and batch number at least for medicinal product bearing the safety features (10).

Records should be made at the time each operation is undertaken.

CHAPTER 5 —   OPERATIONS

5.1.   Principle

All actions taken by wholesale distributors should ensure that the identity of the medicinal product is not lost and that the wholesale distribution of medicinal products is performed according to the information on the outer packaging. The wholesale distributor should use all means available to minimise the risk of falsified medicinal products entering the legal supply chain.

All medicinal products distributed in the EU by a wholesale distributor must be covered by a marketing authorisation granted by the EU or by a Member State (11).

Any distributor, other than the marketing authorisation holder, who imports a medicinal product from another Member State must notify the marketing authorisation holder and the competent authority in the Member State to which the medicinal product will be imported of their intention to import that product (12). All key operations described below should be fully described in the quality system in appropriate documentation.

5.2.   Qualification of suppliers

Wholesale distributors must obtain their supplies of medicinal products only from persons who are themselves in possession of a wholesale distribution authorisation, or who are in possession of a manufacturing authorisation which covers the product in question (13).

Wholesale distributors receiving medicinal products from third countries for the purpose of importation, i.e. for the purpose of placing these products on the EU market, must hold a manufacturing authorisation (14).

Where medicinal products are obtained from another wholesale distributor, the receiving wholesale distributor, must verify that the supplier complies with the principles and guidelines of good distribution practices and that they hold an authorisation for example by using the Union database. If the medicinal product is obtained through brokering, the wholesale distributor must verify that the broker is registered and complies with the requirements in Chapter 10 (15).

Appropriate qualification and approval of suppliers, should be performed prior to any procurement of medicinal products. This should be controlled by a procedure and the results documented and periodically rechecked.

When entering into a new contract with new suppliers, the wholesale distributor should carry out ‘due diligence’ checks in order to assess the suitability, competence and reliability of the other party. Attention should be paid to:

| (i) | the reputation or reliability of the supplier; |
| --- | --- |

(i)

the reputation or reliability of the supplier;

| (ii) | offers of medicinal products more likely to be falsified; |
| --- | --- |

(ii)

offers of medicinal products more likely to be falsified;

| (iii) | large offers of medicinal products which are generally only available in limited quantities; and |
| --- | --- |

(iii)

large offers of medicinal products which are generally only available in limited quantities; and

| (iv) | out-of-range prices. |
| --- | --- |

(iv)

out-of-range prices.

5.3.   Qualification of customers

Wholesale distributors must ensure they supply medicinal products only to persons who are themselves in possession of a wholesale distribution authorisation or who are authorised or entitled to supply medicinal products to the public.

Checks and periodic rechecks may include: requesting copies of customer’s authorisations according to national law, verifying status on an authority website, requesting evidence of qualifications or entitlement according to national legislation.

Wholesale distributors should monitor their transactions and investigate any irregularity in the sales patterns of narcotics, psychotropic substances or other dangerous substances. Unusual sales patterns that may constitute diversion or misuse of medicinal product should be investigated and reported to competent authorities where necessary. Steps should be taken to ensure fulfilment of any public service obligation imposed upon them.

5.4.   Receipt of medicinal products

The purpose of the receiving function is to ensure that the arriving consignment is correct, that the medicinal products originate from approved suppliers and that they have not been visibly damaged during transport.

Medicinal products requiring special storage or security measures should be prioritised and once appropriate checks have been conducted they should be immediately transferred to appropriate storage facilities.

Batches of medicinal products intended for the EU and EEA countries should not be transferred to saleable stock before assurance has been obtained in accordance with written procedures, that they are authorised for sale. For batches coming from another Member State, prior to their transfer to saleable stock, the control report referred to in Article 51(1) of Directive 2001/83/EC or another proof of release to the market in question based on an equivalent system should be carefully checked by appropriately trained personnel.

5.5.   Storage

Medicinal products and, if necessary, healthcare products should be stored separately from other products likely to alter them and should be protected from the harmful effects of light, temperature, moisture and other external factors. Particular attention should be paid to products requiring specific storage conditions.

Incoming containers of medicinal products should be cleaned, if necessary, before storage.

Warehousing operations must ensure appropriate storage conditions are maintained and allow for appropriate security of stocks.

Stock should be rotated according to the ‘first expiry, first out’ (FEFO) principle. Exceptions should be documented.

Medicinal products should be handled and stored in such a manner as to prevent spillage, breakage, contamination and mix-ups. Medicinal products should not be stored directly on the floor unless the package is designed to allow such storage (such as for some medicinal gas cylinders).

Medicinal products that are nearing their expiry date/shelf life should be withdrawn immediately from saleable stock either physically or through other equivalent electronic segregation.

Stock inventories should be performed regularly taking into account national legislation requirements. Stock irregularities should be investigated and documented.

5.6.   Destruction of obsolete goods

Medicinal products intended for destruction should be appropriately identified, held separately and handled in accordance with a written procedure.

Destruction of medicinal products should be in accordance with national or international requirements for handling, transport and disposal of such products.

Records of all destroyed medicinal products should be retained for a defined period.

5.7.   Picking

Controls should be in place to ensure the correct product is picked. The product should have an appropriate remaining shelf life when it is picked.

5.8.   Supply

For all supplies, a document (e.g. delivery note) must be enclosed stating the date; name and pharmaceutical form of the medicinal product, batch number at least for products bearing the safety features; quantity supplied; name and address of the supplier, name and delivery address of the consignee (16) (actual physical storage premises, if different) and applicable transport and storage conditions. Records should be kept so that the actual location of the product can be known.

5.9.   Export to third countries

The export of medicinal products falls within the definition of ‘wholesale distribution’ (17). A person exporting medicinal products must hold a wholesale distribution authorisation or a manufacturing authorisation. This is also the case if the exporting wholesale distributor is operating from a free zone.

The rules for wholesale distribution apply in their entirety in the case of export of medicinal products. However, where medicinal products are exported, they do not need to be covered by a marketing authorisation of the Union or a Member State (18). Wholesalers should take the appropriate measures in order to prevent these medicinal products reaching the Union market. Where wholesale distributors supply medicinal products to persons in third countries, they shall ensure that such supplies are only made to persons who are authorised or entitled to receive medicinal products for wholesale distribution or supply to the public in accordance with the applicable legal and administrative provisions of the country concerned.

CHAPTER 6 —   COMPLAINTS, RETURNS, SUSPECTED FALSIFIED MEDICINAL PRODUCTS AND MEDICINAL PRODUCT RECALLS

6.1.   Principle

All complaints, returns, suspected falsified medicinal products and recalls must be recorded and handled carefully according to written procedures. Records should be made available to the competent authorities. An assessment of returned medicinal products should be performed before any approval for resale. A consistent approach by all partners in the supply chain is required in order to be successful in the fight against falsified medicinal products.

6.2.   Complaints

Complaints should be recorded with all the original details. A distinction should be made between complaints related to the quality of a medicinal product and those related to distribution. In the event of a complaint about the quality of a medicinal product and a potential product defect, the manufacturer and/or marketing authorisation holder should be informed without delay. Any product distribution complaint should be thoroughly investigated to identify the origin of or reason for the complaint.

A person should be appointed to handle complaints and allocated sufficient support personnel.

If necessary, appropriate follow-up actions (including CAPA) should be taken after investigation and evaluation of the complaint, including where required notification to the national competent authorities.

6.3.   Returned medicinal products

Returned products must be handled according to a written, risk-based process taking into account the product concerned, any specific storage requirements and the time elapsed since the medicinal product was originally dispatched. Returns should be conducted in accordance with national law and contractual arrangements between the parties.

Medicinal products which have left the premises of the distributor should only be returned to saleable stock if all of the following are confirmed:

| (i) | the medicinal products are in their unopened and undamaged secondary packaging and are in good condition; have not expired and have not been recalled; |
| --- | --- |

(i)

the medicinal products are in their unopened and undamaged secondary packaging and are in good condition; have not expired and have not been recalled;

| (ii) | medicinal products returned from a customer not holding a wholesale distribution authorisation or from pharmacies authorised to supply medicinal products to the public should only be returned to saleable stock if they are returned within an acceptable time limit, for example 10 days; |
| --- | --- |

(ii)

medicinal products returned from a customer not holding a wholesale distribution authorisation or from pharmacies authorised to supply medicinal products to the public should only be returned to saleable stock if they are returned within an acceptable time limit, for example 10 days;

| (iii) | it has been demonstrated by the customer that the medicinal products have been transported, stored and handled in compliance with their specific storage requirements; |
| --- | --- |

(iii)

it has been demonstrated by the customer that the medicinal products have been transported, stored and handled in compliance with their specific storage requirements;

| (iv) | they have been examined and assessed by a sufficiently trained and competent person authorised to do so; |
| --- | --- |

(iv)

they have been examined and assessed by a sufficiently trained and competent person authorised to do so;

| (v) | the distributor has reasonable evidence that the product was supplied to that customer (via copies of the original delivery note or by referencing invoice numbers, etc.) and the batch number for products bearing the safety features is known, and that there is no reason to believe that the product has been falsified. |
| --- | --- |

(v)

the distributor has reasonable evidence that the product was supplied to that customer (via copies of the original delivery note or by referencing invoice numbers, etc.) and the batch number for products bearing the safety features is known, and that there is no reason to believe that the product has been falsified.

Moreover, for medicinal products requiring specific temperature storage conditions such as low temperature, returns to saleable stock can only be made if there is documented evidence that the product has been stored under the authorised storage conditions throughout the entire time. If any deviation has occurred, a risk assessment has to be performed, on which basis the integrity of the product can be demonstrated. The evidence should cover:

| (i) | delivery to customer; |
| --- | --- |

(i)

delivery to customer;

| (ii) | examination of the product; |
| --- | --- |

(ii)

examination of the product;

| (iii) | opening of the transport packaging; |
| --- | --- |

(iii)

opening of the transport packaging;

| (iv) | return of the product to the packaging; |
| --- | --- |

(iv)

return of the product to the packaging;

| (v) | collection and return to the distributor; |
| --- | --- |

(v)

collection and return to the distributor;

| (vi) | return to the distribution site refrigerator. |
| --- | --- |

(vi)

return to the distribution site refrigerator.

Products returned to saleable stock should be placed such that the ‘first expired first out’ (FEFO) system operates effectively.

Stolen products that have been recovered cannot be returned to saleable stock and sold to customers.

6.4.   Falsified medicinal products

Wholesale distributors must immediately inform the competent authority and the marketing authorisation holder of any medicinal products they identify as falsified or suspect to be falsified (19). A procedure should be in place to this effect. It should be recorded with all the original details and investigated.

Any falsified medicinal products found in the supply chain should immediately be physically segregated and stored in a dedicated area away from all other medicinal products. All relevant activities in relation to such products should be documented and records retained.

6.5.   Medicinal product recalls

The effectiveness of the arrangements for product recall should be evaluated regularly (at least annually).

Recall operations should be capable of being initiated promptly and at any time.

The distributor must follow the instructions of a recall message, which should be approved, if required, by the competent authorities.

Any recall operation should be recorded at the time it is carried out. Records should be made readily available to the competent authorities.

The distribution records should be readily accessible to the person(s) responsible for the recall, and should contain sufficient information on distributors and directly supplied customers (with addresses, phone and/or fax numbers inside and outside working hours, batch numbers at least for medicinal products bearing safety features as required by legislation and quantities delivered), including those for exported products and medicinal product samples.

The progress of the recall process should be recorded for a final report.

CHAPTER 7 —   OUTSOURCED ACTIVITIES

7.1.   Principle

Any activity covered by the GDP guide that is outsourced should be correctly defined, agreed and controlled in order to avoid misunderstandings which could affect the integrity of the product. There must be a written contract between the contract giver and the contract acceptor which clearly establishes the duties of each party.

7.2.   Contract giver

The contract giver is responsible for the activities contracted out.

The contract giver is responsible for assessing the competence of the contract acceptor to successfully carry out the work required and for ensuring by means of the contract and through audits that the principles and guidelines of GDP are followed. An audit of the contract acceptor should be performed before commencement of, and whenever there has been a change to, the outsourced activities. The frequency of audit should be defined based on risk depending on the nature of the outsourced activities. Audits should be permitted at any time.

The contract giver should provide the contract acceptor with all the information necessary to carry out the contracted operations in accordance with the specific product requirements and any other relevant requirements.

7.3.   Contract acceptor

The contract acceptor should have adequate premises and equipment, procedures, knowledge and experience, and competent personnel to carry out the work ordered by the contract giver.

The contract acceptor should not pass to a third party any of the work entrusted to him under the contract without the contract giver’s prior evaluation and approval of the arrangements and an audit of the third party by the contract giver or the contract acceptor. Arrangements made between the contract acceptor and any third party should ensure that the wholesale distribution information is made available in the same way as between the original contract giver and contract acceptor.

The contract acceptor should refrain from any activity which may adversely affect the quality of the product(s) handled for the contract giver.

The contract acceptor must forward any information that can influence the quality of the product(s) to the contract giver in accordance with the requirement of the contract.

CHAPTER 8 —   SELF-INSPECTIONS

8.1.   Principle

Self-inspections should be conducted in order to monitor implementation and compliance with GDP principles and to propose necessary corrective measures.

8.2.   Self-inspections

A self-inspection programme should be implemented covering all aspects of GDP and compliance with the regulations, guidelines and procedures within a defined time frame. Self-inspections may be divided into several individual self-inspections of limited scope.

Self-inspections should be conducted in an impartial and detailed way by designated competent company personnel. Audits by independent external experts may also be useful but may not be used as a substitute for self-inspection.

All self-inspections should be recorded. Reports should contain all the observations made during the inspection. A copy of the report should be provided to the management and other relevant persons. In the event that irregularities and/or deficiencies are observed, their cause should be determined and the corrective and preventive actions (CAPA) should be documented and followed up.

CHAPTER 9 —   TRANSPORTATION

9.1.   Principle

It is the responsibility of the supplying wholesale distributor to protect medicinal products against breakage, adulteration and theft, and to ensure that temperature conditions are maintained within acceptable limits during transport.

Regardless of the mode of transport, it should be possible to demonstrate that the medicines have not been exposed to conditions that may compromise their quality and integrity. A risk-based approach should be utilised when planning transportation.

9.2.   Transportation

The required storage conditions for medicinal products should be maintained during transportation within the defined limits as described by the manufacturers or on the outer packaging.

If a deviation such as temperature excursion or product damage has occurred during transportation, this should be reported to the distributor and recipient of the affected medicinal products. A procedure should also be in place for investigating and handling temperature excursions.

It is the responsibility of the wholesale distributor to ensure that vehicles and equipment used to distribute, store or handle medicinal products are suitable for their use and appropriately equipped to prevent exposure of the products to conditions that could affect their quality and packaging integrity.

There should be written procedures in place for the operation and maintenance of all vehicles and equipment involved in the distribution process, including cleaning and safety precautions.

Risk assessment of delivery routes should be used to determine where temperature controls are required. Equipment used for temperature monitoring during transport within vehicles and/or containers should be maintained and calibrated at regular intervals at least once a year.

Dedicated vehicles and equipment should be used, where possible, when handling medicinal products. Where non-dedicated vehicles and equipment are used, procedures should be in place to ensure that the quality of the medicinal product will not be compromised.

Deliveries should be made to the address stated on the delivery note and into the care or the premises of the consignee. Medicinal products should not be left on alternative premises.

For emergency deliveries outside normal business hours, persons should be designated and written procedures should be available.

Where transportation is performed by a third party, the contract in place should encompass the requirements of Chapter 7. Transportation providers should be made aware by the wholesale distributor of the relevant transport conditions applicable to the consignment. Where the transportation route includes unloading and reloading or transit storage at a transportation hub, particular attention should be paid to temperature monitoring, cleanliness and the security of any intermediate storage facilities.

Provision should be made to minimise the duration of temporary storage while awaiting the next stage of the transportation route.

9.3.   Containers, packaging and labelling

Medicinal products should be transported in containers that have no adverse effect on the quality of the products, and that offer adequate protection from external influences, including contamination.

Selection of a container and packaging should be based on the storage and transportation requirements of the medicinal products; the space required for the amount of medicines; the anticipated external temperature extremes; the estimated maximum time for transportation including transit storage at customs; the qualification status of the packaging and the validation status of the shipping containers.

Containers should bear labels providing sufficient information on handling and storage requirements and precautions to ensure that the products are properly handled and secured at all times. The containers should enable identification of the contents of the containers and the source.

9.4.   Products requiring special conditions

In relation to deliveries containing medicinal products requiring special conditions such as narcotics or psychotropic substances, the wholesale distributor should maintain a safe and secure supply chain for these products in accordance with requirements laid down by the Member States concerned. There should be additional control systems in place for delivery of these products. There should be a protocol to address the occurrence of any theft.

Medicinal products comprising highly active and radioactive materials should be transported in safe, dedicated and secure containers and vehicles. The relevant safety measures should be in accordance with international agreements and national legislation.

For temperature-sensitive products, qualified equipment (e.g. thermal packaging, temperature-controlled containers or temperature-controlled vehicles) should be used to ensure correct transport conditions are maintained between the manufacturer, wholesale distributor and customer.

If temperature-controlled vehicles are used, the temperature monitoring equipment used during transport should be maintained and calibrated at regular intervals. Temperature mapping under representative conditions should be carried out and should take into account seasonal variations.

If requested, customers should be provided with information to demonstrate that products have complied with the temperature storage conditions.

If cool-packs are used in insulated boxes, they need to be located such that the product does not come in direct contact with the cool-pack. Staff must be trained on the procedures for assembly of the insulated boxes (seasonal configurations) and on the reuse of cool-packs.

There should be a system in place to control the re-use of cool-packs to ensure that incompletely cooled packs are not used in error. There should be adequate physical segregation between frozen and chilled ice packs.

The process for delivery of sensitive products and control of seasonal temperature variations should be described in a written procedure.

CHAPTER 10 —   SPECIFIC PROVISIONS FOR BROKERS
   (20)

10.1.   Principle

A ‘broker’ is a person involved in activities in relation to the sale or purchase of medicinal products, except for wholesale distribution, that do not include physical handling and that consist of negotiating independently and on behalf of another legal or natural person (21).

Brokers are subject to a registration requirement. They must have a permanent address and contact details in the Member State where they are registered (22). They must notify the competent authority of any changes to those details without unnecessary delay.

By definition, brokers do not procure, supply or hold medicines. Therefore, requirements for premises, installations and equipment as set out in Directive 2001/83/EC do not apply. However, all other rules in Directive 2001/83/EC that apply to wholesale distributors also apply to brokers.

10.2.   Quality system

The quality system of a broker should be defined in writing, approved and kept up-to-date. It should set out responsibilities, processes and risk management in relation to their activities.

The quality system should include an emergency plan which ensures effective recall of medicinal products from the market ordered by the manufacturer or the competent authorities or carried out in cooperation with the manufacturer or marketing authorisation holder for the medicinal product concerned (23). The competent authorities must be immediately informed of any suspected falsified medicines offered in the supply chain (24).

10.3.   Personnel

Any member of personnel involved in the brokering activities should be trained in the applicable EU and national legislation and in the issues concerning falsified medicinal products.

10.4.   Documentation

The general provisions on documentation in Chapter 4 apply.

In addition, at least the following procedures and instructions, along with the corresponding records of execution, should be in place:

| (i) | procedure for complaints handling; |
| --- | --- |

(i)

procedure for complaints handling;

| (ii) | procedure for informing competent authorities and marketing authorisation holders of suspected falsified medicinal products; |
| --- | --- |

(ii)

procedure for informing competent authorities and marketing authorisation holders of suspected falsified medicinal products;

| (iii) | procedure for supporting recalls; |
| --- | --- |

(iii)

procedure for supporting recalls;

| (iv) | procedure for ensuring that medicinal products brokered have a marketing authorisation; |
| --- | --- |

(iv)

procedure for ensuring that medicinal products brokered have a marketing authorisation;

| (v) | procedure for verifying that their supplying wholesale distributors hold a distribution authorisation, their supplying manufacturers or importers hold a manufacturing authorisation and their customers are authorised to supply medicinal products in the Member State concerned; |
| --- | --- |

(v)

procedure for verifying that their supplying wholesale distributors hold a distribution authorisation, their supplying manufacturers or importers hold a manufacturing authorisation and their customers are authorised to supply medicinal products in the Member State concerned;

| (vi) | records should be kept either in the form of purchase/sales invoices or on computer, or in any other form for any transaction in medicinal products brokered and should contain at least the following information: date; name of the medicinal product; quantity brokered; name and address of the supplier and the customer; and batch number at least for products bearing the safety features. |
| --- | --- |

(vi)

records should be kept either in the form of purchase/sales invoices or on computer, or in any other form for any transaction in medicinal products brokered and should contain at least the following information: date; name of the medicinal product; quantity brokered; name and address of the supplier and the customer; and batch number at least for products bearing the safety features.

Records should be made available to the competent authorities, for inspection purposes, for the period stated in national legislation but at least five years.

CHAPTER 11 —   FINAL PROVISIONS

These Guidelines replace the Guidelines on Good Distribution Practice of medicinal products for human use, published on 1 March 1994 (25) and the Guidelines of 7 March 2013 on Good Distribution Practice of medicinal products for human use (26).

These Guidelines will be applied from the first day following their publication in the Official Journal of the European Union.

---

(1)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, OJ L 311, 28.11.2001, p. 67.

(2)  Guidelines on Good Distribution Practice of medicinal products for human use, OJ C 63, 1.3.1994, p. 4.

(3)  Guidelines of 7 March 2013 on Good Distribution Practice of medicinal products for human use, OJ C 68, 8.3.2013, p. 1.

(4)  Directive 2011/62/EU of the European Parliament and of the Council amending Directive 2001/83/EC as regards the prevention of the entry into the legal supply chain of falsified medicinal products, OJ L 174, 1.7.2011, p. 74.

(5)  Article 80(h) of Directive 2001/83/EC.

(6)  Article 79(b) of Directive 2001/83/EC.

(7)  Article 83 of Directive 2001/83/EC.

(8)  Article 79(a) of Directive 2001/83/EC.

(9)  OJ L 281, 23.11.1995, p. 31.

(10)  Article 80(e) and Article 82 of Directive 2001/83/EC.

(11)  Article 76(1) and (2) of Directive 2001/83/EC.

(12)  Article 76(3) of Directive 2001/83/EC.

(13)  Article 80(b) of Directive 2001/83/EC.

(14)  Article 40(3) of Directive 2001/83/EC.

(15)  Article 80, fourth paragraph of Directive 2001/83/EC.

(16)  Article 82 of Directive 2001/83/EC.

(17)  Article 1(17) of Directive 2001/83/EC.

(18)  Article 85a of Directive 2001/83/EC.

(19)  Article 80(i) of Directive 2001/83/EC.

(20)  Article 85b(3) of Directive 2001/83/EC.

(21)  Article 1(17a) of Directive 2001/83/EC.

(22)  Article 85b of Directive 2001/83/EC.

(23)  Article 80(d) of Directive 2001/83/EC.

(24)  Article 85b(1), third subparagraph of Directive 2001/83/EC.

(25)  OJ C 63, 1.3.1994, p. 4.

(26)  OJ C 68, 8.3.2013, p. 1.

---

ANNEX

Glossary of terms

| Terms | Definition |
| --- | --- |
| Good Distribution Practice (GDP) | GDP is that part of quality assurance which ensures that the quality of medicinal products is maintained throughout all stages of the supply chain from the site of manufacturer to the pharmacy or person authorised or entitled to supply medicinal products to the public. |
| Export procedure | Export procedure: allow Community goods to leave the customs territory of the Union. For the purpose of these guidelines, the supply of medicines from EU Member State to a contracting State of the European Economic Area is not considered as export. |
| Falsified medicinal product (1) | Any medicinal product with a false representation of:






  (a) | its identity, including its packaging and labelling, its name or its composition as regards any of the ingredients including excipients and the strength of those ingredients; |

Terms

Definition

Good Distribution Practice (GDP)

GDP is that part of quality assurance which ensures that the quality of medicinal products is maintained throughout all stages of the supply chain from the site of manufacturer to the pharmacy or person authorised or entitled to supply medicinal products to the public.

Export procedure

Export procedure: allow Community goods to leave the customs territory of the Union. For the purpose of these guidelines, the supply of medicines from EU Member State to a contracting State of the European Economic Area is not considered as export.

Falsified medicinal product (1)

Any medicinal product with a false representation of:

(a)

its identity, including its packaging and labelling, its name or its composition as regards any of the ingredients including excipients and the strength of those ingredients;

| (b) | its source, including its manufacturer, its country of manufacturing, its country of origin or its marketing authorisation holder; or |
| --- | --- |

(b)

its source, including its manufacturer, its country of manufacturing, its country of origin or its marketing authorisation holder; or

| (c) | its history, including the records and documents relating to the distribution channels used. |
| --- | --- |

(c)

its history, including the records and documents relating to the distribution channels used.

Free zones and free warehouses (2)

Free zones and free warehouses are parts of the customs territory of the Community or premises situated in that territory and separated from the rest of it in which:

| (a) | Community goods are considered, for the purpose of import duties and commercial policy import measures, as not being on Community customs territory, provided they are not released for free circulation or placed under another customs procedure or used or consumed under conditions other than those provided for in customs regulations; |
| --- | --- |

(a)

Community goods are considered, for the purpose of import duties and commercial policy import measures, as not being on Community customs territory, provided they are not released for free circulation or placed under another customs procedure or used or consumed under conditions other than those provided for in customs regulations;

| (b) | Community goods for which such provision is made under Community legislation governing specific fields qualify, by virtue of being placed in a free zone or free warehouse, for measures normally attaching to the export of goods. |
| --- | --- |

(b)

Community goods for which such provision is made under Community legislation governing specific fields qualify, by virtue of being placed in a free zone or free warehouse, for measures normally attaching to the export of goods.

Holding

Storing medicinal products

Transport

Moving medicinal products between two locations without storing them for unjustified periods of time

Procuring

Obtaining, acquiring, purchasing or buying medicinal products from manufacturers, importers or other wholesale distributors

Qualification

Action of proving that any equipment works correctly and actually leads to the expected results.

The word ‘validation’ is sometimes widened to incorporate the concept of qualification.

(Defined in EudraLex Volume 4 Glossary to the GMP Guidelines)

Supplying

All activities of providing, selling, donating medicinal products to wholesalers, pharmacists, or persons authorised or entitled to supply medicinal products to the public

Quality risk management

A systematic process for the assessment, control, communication and review of risks to the quality of the drug (medicinal) product across the product lifecycle

Quality system

The sum of all aspects of a system that implements quality policy and ensures that quality objectives are met

(International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Q9)

Validation

Action of proving that any procedure, process, equipment, material, activity or system actually leads to the expected results (see also ‘qualification’)

(Defined in EudraLex Volume 4 Glossary to the GMP Guidelines)

---

(1)  Article 1(33) of Directive 2001/83/EC.

(2)  Articles 166 to 181 of Council Regulation (EEC) No 2913/92 of 12 October 1992 establishing the Community Customs Code (OJ L 302, 19.10.1992, p. 1).

---

| 23.11.2013 | EN | Official Journal of the European Union | C 343/15 |
| --- | --- | --- | --- |

23.11.2013

EN

Official Journal of the European Union

C 343/15

---

Non-opposition to a notified concentration

(Case COMP/M.6922 — Triton/Logstor)

(Text with EEA relevance)

2013/C 343/02

On 23 August 2013, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32013M6922. EUR-Lex is the online access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32013M6922. EUR-Lex is the online access to the European law.

---

| 23.11.2013 | EN | Official Journal of the European Union | C 343/15 |
| --- | --- | --- | --- |

23.11.2013

EN

Official Journal of the European Union

C 343/15

---

Non-opposition to a notified concentration

(Case COMP/M.6995 — Reggeborgh/Boskalis/VSMC)

(Text with EEA relevance)

2013/C 343/03

On 29 October 2013, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32013M6995. EUR-Lex is the online access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32013M6995. EUR-Lex is the online access to the European law.

---

| 23.11.2013 | EN | Official Journal of the European Union | C 343/16 |
| --- | --- | --- | --- |

23.11.2013

EN

Official Journal of the European Union

C 343/16

---

Non-opposition to a notified concentration

(Case COMP/M.7069 — Ares/OTPP/CPG)

(Text with EEA relevance)

2013/C 343/04

On 11 November 2013, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32013M7069. EUR-Lex is the online access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32013M7069. EUR-Lex is the online access to the European law.

---

| 23.11.2013 | EN | Official Journal of the European Union | C 343/16 |
| --- | --- | --- | --- |

23.11.2013

EN

Official Journal of the European Union

C 343/16

---

Non-opposition to a notified concentration

(Case COMP/M.7031 — Eurenco/Maxamchem/Manuco)

(Text with EEA relevance)

2013/C 343/05

On 19 November 2013, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32013M7031. EUR-Lex is the online access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32013M7031. EUR-Lex is the online access to the European law.

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 23.11.2013 | EN | Official Journal of the European Union | C 343/17 |
| --- | --- | --- | --- |

23.11.2013

EN

Official Journal of the European Union

C 343/17

---

Euro exchange rates (1)

22 November 2013

2013/C 343/06

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,3518 |
| JPY | Japanese yen | 136,74 |
| DKK | Danish krone | 7,4586 |
| GBP | Pound sterling | 0,83440 |
| SEK | Swedish krona | 8,8948 |
| CHF | Swiss franc | 1,2302 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 8,2065 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 27,258 |
| HUF | Hungarian forint | 297,98 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,7028 |
| PLN | Polish zloty | 4,1978 |
| RON | Romanian leu | 4,4490 |
| TRY | Turkish lira | 2,7251 |
| AUD | Australian dollar | 1,4746 |
| CAD | Canadian dollar | 1,4249 |
| HKD | Hong Kong dollar | 10,4802 |
| NZD | New Zealand dollar | 1,6575 |
| SGD | Singapore dollar | 1,6916 |
| KRW | South Korean won | 1 434,85 |
| ZAR | South African rand | 13,6485 |
| CNY | Chinese yuan renminbi | 8,2385 |
| HRK | Croatian kuna | 7,6453 |
| IDR | Indonesian rupiah | 15 509,47 |
| MYR | Malaysian ringgit | 4,3539 |
| PHP | Philippine peso | 59,388 |
| RUB | Russian rouble | 44,2985 |
| THB | Thai baht | 43,035 |
| BRL | Brazilian real | 3,0918 |
| MXN | Mexican peso | 17,6167 |
| INR | Indian rupee | 84,9890 |

Currency

Exchange rate

USD

US dollar

1,3518

JPY

Japanese yen

136,74

DKK

Danish krone

7,4586

GBP

Pound sterling

0,83440

SEK

Swedish krona

8,8948

CHF

Swiss franc

1,2302

ISK

Iceland króna

NOK

Norwegian krone

8,2065

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

27,258

HUF

Hungarian forint

297,98

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,7028

PLN

Polish zloty

4,1978

RON

Romanian leu

4,4490

TRY

Turkish lira

2,7251

AUD

Australian dollar

1,4746

CAD

Canadian dollar

1,4249

HKD

Hong Kong dollar

10,4802

NZD

New Zealand dollar

1,6575

SGD

Singapore dollar

1,6916

KRW

South Korean won

1 434,85

ZAR

South African rand

13,6485

CNY

Chinese yuan renminbi

8,2385

HRK

Croatian kuna

7,6453

IDR

Indonesian rupiah

15 509,47

MYR

Malaysian ringgit

4,3539

PHP

Philippine peso

59,388

RUB

Russian rouble

44,2985

THB

Thai baht

43,035

BRL

Brazilian real

3,0918

MXN

Mexican peso

17,6167

INR

Indian rupee

84,9890

---

(1)  Source: reference exchange rate published by the ECB.

---

V Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

| 23.11.2013 | EN | Official Journal of the European Union | C 343/18 |
| --- | --- | --- | --- |

23.11.2013

EN

Official Journal of the European Union

C 343/18

---

Prior notification of a concentration

(Case COMP/M.7107 — Cordes & Graefe/Pompac/Comafranc)

(Text with EEA relevance)

2013/C 343/07

| 1. | On 18 November 2013 the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Cordes & Graefe KG (Germany), the holding company of the Cordes & Graefe Group, acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertakings Pompac SA (France) and Comafranc SA (France), the holding companies of the Pompac Group, by way of purchase of shares. |
| --- | --- |

1.

On 18 November 2013 the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Cordes & Graefe KG (Germany), the holding company of the Cordes & Graefe Group, acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertakings Pompac SA (France) and Comafranc SA (France), the holding companies of the Pompac Group, by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | Cordes & Graefe Group: provision of wholesale services and products for all aspects of household technology in the areas of sanitary fittings, heating, air conditioning/ ventilation, electrical equipment, installation, roofing technology, as well as excavation and industrial technology. It is active mainly in Germany, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

Cordes & Graefe Group: provision of wholesale services and products for all aspects of household technology in the areas of sanitary fittings, heating, air conditioning/ ventilation, electrical equipment, installation, roofing technology, as well as excavation and industrial technology. It is active mainly in Germany,

| — | Pompac Group: active throughout France as a wholesaler for products in the areas of sanitary fittings, heating, tiling and electrical equipment. The undertaking also trades in building materials in eastern France. |
| --- | --- |

—

Pompac Group: active throughout France as a wholesaler for products in the areas of sanitary fittings, heating, tiling and electrical equipment. The undertaking also trades in building materials in eastern France.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than ten days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7107 — Cordes & Graefe/Pompac/Comafranc, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than ten days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7107 — Cordes & Graefe/Pompac/Comafranc, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

---

| 23.11.2013 | EN | Official Journal of the European Union | C 343/19 |
| --- | --- | --- | --- |

23.11.2013

EN

Official Journal of the European Union

C 343/19

---

Prior notification of a concentration

(Case COMP/M.6981 — TPG/Servco/Fender)

Candidate case for simplified procedure

(Text with EEA relevance)

2013/C 343/08

| 1. | On 18 November 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertakings TPG Slowhand, LP (‘TPG’, USA), an investment vehicle of TPG Growth II LP, which belongs to the TPG Group, and Servco Pacific Inc (‘Servco’, USA) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the undertaking Fender Musical Instruments Corporation (‘Fender’, USA) by way of purchase of shares. |
| --- | --- |

1.

On 18 November 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertakings TPG Slowhand, LP (‘TPG’, USA), an investment vehicle of TPG Growth II LP, which belongs to the TPG Group, and Servco Pacific Inc (‘Servco’, USA) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the undertaking Fender Musical Instruments Corporation (‘Fender’, USA) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for TPG Group: private investment firm investing in a broad range of industries including inter alia: consumer, retail, technology, internet, healthcare, energy, clean-tech and renewables, transportation, industrials, and business services, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for TPG Group: private investment firm investing in a broad range of industries including inter alia: consumer, retail, technology, internet, healthcare, energy, clean-tech and renewables, transportation, industrials, and business services,

| — | for Servco: automotive retailing, parts and service, home products retailing and commercial insurance brokerage, |
| --- | --- |

—

for Servco: automotive retailing, parts and service, home products retailing and commercial insurance brokerage,

| — | for Fender: fretted instruments, guitar amplifiers, percussion instruments and accessories. |
| --- | --- |

—

for Fender: fretted instruments, guitar amplifiers, percussion instruments and accessories.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6981 — TPG/Servco/Fender, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6981 — TPG/Servco/Fender, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

(2)  OJ C 56, 5.3.2005, p. 32 (‘Notice on a simplified procedure’).

---

| 23.11.2013 | EN | Official Journal of the European Union | C 343/20 |
| --- | --- | --- | --- |

23.11.2013

EN

Official Journal of the European Union

C 343/20

---

Prior notification of a concentration

(Case COMP/M.7079 — Bulgaria Airways Group/Swissport International/Swissport Bulgaria)

Candidate case for simplified procedure

(Text with EEA relevance)

2013/C 343/09

| 1. | On 18 November 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Bulgarian Airways Group EAD (‘BAG’, Bulgaria) and Swissport International AG (‘Swissport’, Switzerland) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Swissport Bulgaria AD (‘Swissport Bulgaria’, Bulgaria) by way of purchase of shares. |
| --- | --- |

1.

On 18 November 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Bulgarian Airways Group EAD (‘BAG’, Bulgaria) and Swissport International AG (‘Swissport’, Switzerland) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Swissport Bulgaria AD (‘Swissport Bulgaria’, Bulgaria) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | BAG's core business consists of international and domestic air transport of passengers and cargo as well as related activities. It controls the airline Bulgaria Air AD. BAG is ultimately controlled by the Chim Invest Institute, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

BAG's core business consists of international and domestic air transport of passengers and cargo as well as related activities. It controls the airline Bulgaria Air AD. BAG is ultimately controlled by the Chim Invest Institute,

| — | Swissport is a provider of airport ground handling, cargo handling and related services to airlines. Swissport is owned and controlled by PAI partners SAS, |
| --- | --- |

—

Swissport is a provider of airport ground handling, cargo handling and related services to airlines. Swissport is owned and controlled by PAI partners SAS,

| — | Swissport Bulgaria is a provider of ground handling, cargo handling, and related services to airlines at the Letishte Sofia-Vrazhdebna airport in Sofia. |
| --- | --- |

—

Swissport Bulgaria is a provider of ground handling, cargo handling, and related services to airlines at the Letishte Sofia-Vrazhdebna airport in Sofia.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7079 — Bulgaria Airways Group/Swissport International/Swissport Bulgaria, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7079 — Bulgaria Airways Group/Swissport International/Swissport Bulgaria, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

(2)  OJ C 56, 5.3.2005, p. 32 (‘Notice on a simplified procedure’).

---

OTHER ACTS

European Commission

| 23.11.2013 | EN | Official Journal of the European Union | C 343/21 |
| --- | --- | --- | --- |

23.11.2013

EN

Official Journal of the European Union

C 343/21

---

Reply to complaint CHAP(2013) 3076

2013/C 343/10

| 1. | The European Commission has received, and continues to receive, a series of complaints about the welfare and management of stray dogs in Romania, which it has registered under reference CHAP(2013) 3076 (see acknowledgement at OJ C 314, 29.10.2013, p. 9). |
| --- | --- |

1.

The European Commission has received, and continues to receive, a series of complaints about the welfare and management of stray dogs in Romania, which it has registered under reference CHAP(2013) 3076 (see acknowledgement at OJ C 314, 29.10.2013, p. 9).

| 2. | In order to respond swiftly and inform those concerned, while making the most economical use of administrative resources, the Commission is publishing this reply in the Official Journal of the European Union, and on the Internet at:
  http://ec.europa.eu/eu_law/complaints/receipt/index_en.htm |
| --- | --- |

2.

In order to respond swiftly and inform those concerned, while making the most economical use of administrative resources, the Commission is publishing this reply in the Official Journal of the European Union, and on the Internet at:

http://ec.europa.eu/eu_law/complaints/receipt/index_en.htm

| 3. | The welfare and management of stray animal populations is not governed by EU rules and remains under the sole responsibility of the Member States. In particular, Article 13 of the Treaty on the Functioning of the European Union, which requires full regard for the welfare requirements of animals when formulating and implementing some EU policies, does not provide a legal base permitting all animal welfare issues to be addressed. |
| --- | --- |

3.

The welfare and management of stray animal populations is not governed by EU rules and remains under the sole responsibility of the Member States. In particular, Article 13 of the Treaty on the Functioning of the European Union, which requires full regard for the welfare requirements of animals when formulating and implementing some EU policies, does not provide a legal base permitting all animal welfare issues to be addressed.

| 4. | The Commission supports the work of the World Organisation for Animal Health (OIE) on guidelines for the control of stray dog populations, highlighting the important role of local government agencies for the enforcement of legislation relating to dog ownership land indicating the bodies responsible for developing and implementing appropriate training to regulate dog capture, transport, and holding as well as minimum housing and care criteria. The guidelines emphasise the need for parallel approaches in controlling stray dog populations and call for killing to be carried out in a humane way when necessary, not being a sustainable strategy if performed alone. Each Member State, as a member of the OIE, considers how most appropriately to use these international guidelines in their national context. The Commission will continue to support the work of the OIE Regional Platform on Animal Welfare for Europe, assisting OIE member countries in Eastern Europe, including Romania, to achieve compliance with these standards. |
| --- | --- |

4.

The Commission supports the work of the World Organisation for Animal Health (OIE) on guidelines for the control of stray dog populations, highlighting the important role of local government agencies for the enforcement of legislation relating to dog ownership land indicating the bodies responsible for developing and implementing appropriate training to regulate dog capture, transport, and holding as well as minimum housing and care criteria. The guidelines emphasise the need for parallel approaches in controlling stray dog populations and call for killing to be carried out in a humane way when necessary, not being a sustainable strategy if performed alone. Each Member State, as a member of the OIE, considers how most appropriately to use these international guidelines in their national context. The Commission will continue to support the work of the OIE Regional Platform on Animal Welfare for Europe, assisting OIE member countries in Eastern Europe, including Romania, to achieve compliance with these standards.

| 5. | Systematic and common information and education strategies on dog welfare are supported by the Commission cooperating with others to develop the ‘CARODOG’ website (http://www.carodog.eu), an informative platform on canine population management leading to responsible animal ownership as a basic principle for the promotion of companion animal welfare in the EU. |
| --- | --- |

5.

Systematic and common information and education strategies on dog welfare are supported by the Commission cooperating with others to develop the ‘CARODOG’ website (http://www.carodog.eu), an informative platform on canine population management leading to responsible animal ownership as a basic principle for the promotion of companion animal welfare in the EU.

| 6. | The EU rules on the protection of animals at the time of killing (Council Regulation (EC) No 1099/2009) deal specifically with the killing of animals in slaughterhouses and those kept for farming purposes. Animals killed under other circumstances are not covered by this Regulation. |
| --- | --- |

6.

The EU rules on the protection of animals at the time of killing (Council Regulation (EC) No 1099/2009) deal specifically with the killing of animals in slaughterhouses and those kept for farming purposes. Animals killed under other circumstances are not covered by this Regulation.

| 7. | The Commission will continue to pursue the work mentioned above, to which it attaches great importance, but will close the complaints as the grievances fall outside the scope of EU law. |
| --- | --- |

7.

The Commission will continue to pursue the work mentioned above, to which it attaches great importance, but will close the complaints as the grievances fall outside the scope of EU law.

---